>

Nebulisation of Antisense Oligonucleotide (ASO) Danvatirsen with NebuFlow acoustic platform

Nebulisation of Antisense Oligonucleotide (ASO) Danvatirsen with NebuFlow acoustic platform

NebuFlow preserves the biologicalactivity (potency) and structure of the ASO (Purity and PO/PS ratio).

Antisense oligonucleotides (ASOs) are transforming precision medicine through selective gene silencing, but their inhaled delivery is limited by shear-induced degradation during aerosolisation. Here, we demonstrate the feasibility of nebulising Danvatirsen, a 16-mer gapmer ASO, using Nebu-Flow's novel aerosolisation platform. Post-nebulisation analyses confirmed preservation of both structural integrity and biological activity. These results demonstrate the potential of this platform to enable inhaled ASO delivery, supporting targeted treatment of respiratory diseases.

Sign up for our latest news and updates

By signing up you agree to our privacy policy.

© 2026 Acu-Flow Limited (trading as Nebu-Flow®) Registered number: SC624449

Sign up for our latest news and updates

By signing up you agree to our privacy policy.

© 2026 Acu-Flow Limited (trading as Nebu-Flow®) Registered number: SC624449

Sign up for our latest news and updates

By signing up you agree to our privacy policy.

© 2026 Acu-Flow Limited (trading as Nebu-Flow®) Registered number: SC624449

Sign up for our latest news and updates

By signing up you agree to our privacy policy.

© 2026 Acu-Flow Limited (trading as Nebu-Flow®) Registered number: SC624449